Overview

Company Overview

OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

Investment Highlights

  • Advancing a lead portfolio of gene therapies for cancer
  • Platform focused on reversing tumor immune suppression
  • Phase II clinical programs focused on addressing unmet need of T-cell poor tumors
  • Clinical data demonstrates proof of concept of the technology
  • Rapid preclinical development platform
  • Experienced leadership team

Latest Financial Results

Stock Information

Symbol

NASDAQ: ONCS

Price

Loading...

Change

Loading...

MKT Cap

Loading...

Volume

Loading...